[Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].

Abstract

This article contains biological, epidemiological and clinical data on multiple myeloma and the role of proangiogenetic cytokines in the development of this neoplasm. The role of angiogenesis in the transformation and development of multiple myeloma is a topic which is presently readily studied in leading scientific centres in many parts of the world. Serum and bone marrow levels of cytokines such as VEGF, b-FGF, IL-6, sIL-6R, HGFare raised in patients with multiple myeloma as compared to healthy subjects; their values correlate with the severity of disease and are presently recognised as prognostic factors. Thalidomide has anti-inflammatory, immuno-modulating and antiangiogeneic properties but the mechanism of its action is not yet completely understood. Thalidomide is presently used in therapy of patients with resistant and relapsed multiple myeloma with very promising results.

• Authors: Artur Jurczyszyn, Teresa Wolska-Smoleń, Aleksander B Skotnicki
• Journal: Przeglad lekarski (Przegl Lek) Vol. 60 Issue 8 Pg. 542-7 ( 2003) ISSN: 0033-2240 [Print] Poland
• Vernacular Title: Szpiczak mnogi--rola angiogenezy i zastosowanie talidomidu.
• PMID: 14974349 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Angiogenesis Inhibitors
• Carrier Proteins
• Intercellular Signaling Peptides and Proteins
• Interleukin-6
• Receptors, Interleukin-6
• Vascular Endothelial Growth Factor A
• FGFBP1 protein, human
• Thalidomide

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Carrier Proteins (metabolism)
• Humans
• Intercellular Signaling Peptides and Proteins
• Interleukin-6 (metabolism)
• Multiple Myeloma (drug therapy, metabolism, physiopathology)
• Receptors, Interleukin-6 (metabolism)
• Thalidomide (therapeutic use)
• Vascular Endothelial Growth Factor A (metabolism)